Botulinum toxin A: Muscular atrophy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1400, 2012-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Pathogenic Mechanisms and Therapeutic Strategies in Spinobulbar Muscular Atrophy

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. : 1146-1156

Bentham Science Publishers

Access to resources Recommend Favorite

Developments in the discovery of drugs for spinal muscular atrophy: successful beginnings and future prospects

By Pruss Rebecca M.  

Expert Opinion on Drug Discovery, Vol. 6, Iss. 8, 2011-08 ,pp. : 827-837

Informa Healthcare

Access to resources Recommend Favorite

Sorafenib

By Rini Brian I  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 4, 2006-03 ,pp. : 453-461

Informa Healthcare

Access to resources Recommend Favorite

Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib

By Brüning Ansgar   Burger Petra   Vogel Marianne   Gingelmaier Andrea   Friese Klaus   Burges Alexander  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 535-542

Springer Publishing Company

Access to resources Recommend Favorite